trending Market Intelligence /marketintelligence/en/news-insights/trending/8atk-cxoebqbmozfctpepg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

GSK invests in British startup Sitryx

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

GSK invests in British startup Sitryx

GlaxoSmithKline PLC and a syndicate of investors co-led by SV Health Investors LLC and Sofinnova Partners invested $30 million in Sitryx.

The British pharmaceutical company was raising cash via the first round of institutional funding, the so-called series A, to advance therapies to treat severe diseases including cancer and autoimmune conditions.

Sitryx was co-founded by a team of scientists from Europe and the U.S. with seed funding from SV Health investors. Its area of focus is immunometabolism therapies that have the potential of altering metabolic pathways in the body to fight disease.

GSK Senior Vice President of Research John Lepore said the investment in Sitryx will allow the British drugmaker to build on its existing collaboration with the company.

GSK has supported the development of Sitryx's portfolio through access to its technologies and the licensing of intellectual property, including chemical matter.